Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Results suggest SSRIs enhance the efficacy of SPL026 when administered to MDD patients on a…
Cybin to Acquire Small Pharma Inc.
Cybin to acquire Small Pharma creating an international clinical-stage leader in novel psychedelic therapeutics.
Small Pharma Reports Fiscal First Quarter 2024 Highlights
Financial highlights and recent business and R&D highlights.
Small Pharma Announces Management Team Change
Mr. Peter Rands, co-founder and former CEO, has left his positions as an executive officer…
Small Pharma Announces SPL028 R&D Strategy Update
Preliminary findings from ongoing Phase I trial of SPL028 indicate potential for a unique therapeutic…
Small Pharma Reports Financial Results for Fiscal Year End and Recent Business Highlights
Multiple clinical milestones achieved with operational efficiencies underway.
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
5 new patent grants with 3 expected upcoming patent grants in May.
May 2023 Latest News Round-up
A highlight of recent news and events across April and May.
Small Pharma to present at upcoming CINP World of Congress of Neuropsychopharmacology
Dr. Carol Routledge will present a poster on our Phase IIa data.
April 2023 Company Update
A highlight of recent news and events so far.